Cargando…

Recurrent ovarian cancer in the era of poly-ADP ribose polymerase inhibitors: time to re-assess established clinical practices

Detalles Bibliográficos
Autores principales:	Bartoletti, M., Cecere, S.C., Musacchio, L., Sorio, R., Puglisi, F., Pignata, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100608/ https://www.ncbi.nlm.nih.gov/pubmed/33930658 http://dx.doi.org/10.1016/j.esmoop.2021.100135

Ejemplares similares

Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer
por: Markman, Maurie
Publicado: (2018)

Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents
por: Matanes, Emad, et al.
Publicado: (2021)

Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment
por: Papa, Anselmo, et al.
Publicado: (2016)

Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
por: Boussios, Stergios, et al.
Publicado: (2020)

Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer
por: Dong, Ruihong, et al.
Publicado: (2023)

RNA regulation by Poly(ADP-ribose) polymerases
por: Bock, Florian J., et al.
Publicado: (2015)

Mitotic functions of poly(ADP-ribose) polymerases
por: Slade, Dea
Publicado: (2019)

The Antiviral Activities of Poly-ADP-Ribose Polymerases
por: Malgras, Mathilde, et al.
Publicado: (2021)

Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma
por: Vormoor, Britta, et al.
Publicado: (2014)

Role of poly(ADP-ribose) polymerases in male reproduction
por: Celik-Ozenci, Ciler, et al.
Publicado: (2013)

Stability of centrosome numbers in poly(ADP-ribose) polymerase-1- and poly(ADP-ribose) glycohydrolase-deficient mouse ES cells
por: Ogino, Hideki, et al.
Publicado: (2004)

Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations
por: Xu, Qin, et al.
Publicado: (2021)

Loss of amplified genes by poly(ADP-ribose) polymerase inhibitors.
por: Nagao, M, et al.
Publicado: (1991)

Targeting poly(ADP-ribose) polymerase activity for cancer therapy
por: Mégnin-Chanet, Frédérique, et al.
Publicado: (2010)

Lipoxygenases and Poly(ADP-Ribose) Polymerase in Amyloid Beta Cytotoxicity
por: Strosznajder, Joanna B., et al.
Publicado: (2011)

Analysis of Poly(ADP-Ribose) Polymerases in Arabidopsis Telomere Biology
por: Boltz, Kara A., et al.
Publicado: (2014)

The Role of Poly(ADP-ribose) Polymerase-1 in Rheumatoid Arthritis
por: García, Samuel, et al.
Publicado: (2015)

Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
por: Jannetti, Stephen A., et al.
Publicado: (2020)

Poly(ADP-Ribose) Polymerase-3 Regulates Regeneration in Planarians
por: Barghouth, Paul G., et al.
Publicado: (2020)

An attempt to establish real-world databases of poly(ADP-ribose) polymerase inhibitors for advanced or recurrent epithelial ovarian cancer: the Japanese Gynecologic Oncology Group
por: Shimada, Muneaki, et al.
Publicado: (2023)

New Facets in the Regulation of Gene Expression by ADP-Ribosylation and Poly(ADP-ribose) Polymerases
por: Ryu, Keun Woo, et al.
Publicado: (2015)

Pancreatic β-Cell Death, Regeneration and Insulin Secretion: Roles of Poly(ADP-Ribose) Polymerase and Cyclic ADP-Ribose
por: Takasawa, Shin, et al.
Publicado: (2002)

Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
por: Boussios, Stergios, et al.
Publicado: (2020)

The role of poly (ADP-ribose) polymerase in ventilator-induced lung injury
por: Vaneker, Michiel, et al.
Publicado: (2008)

Poly(ADP-ribose) polymerase inhibitor development: are we in the right direction?
por: Plummer, R
Publicado: (2011)

Evolutionary history of the poly(ADP-ribose) polymerase gene family in eukaryotes
por: Citarelli, Matteo, et al.
Publicado: (2010)

Poly (ADP-Ribose) Polymerase Mediates Diabetes-Induced Retinal Neuropathy
por: Mohammad, Ghulam, et al.
Publicado: (2013)

Poly(ADP-Ribose) Polymerase 1: Cellular Pluripotency, Reprogramming, and Tumorogenesis
por: Jiang, Bo-Hua, et al.
Publicado: (2015)

Multiple facets of poly(ADP-ribose) polymerase-1 in neurological diseases
por: Sriram, Chandra Shaker, et al.
Publicado: (2015)

The promising role of poly(ADP-ribose) polymerase inhibitors in prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2016)

Current status of poly(ADP-ribose) polymerase inhibitors and future directions
por: Ohmoto, Akihiro, et al.
Publicado: (2017)

Poly(ADP-Ribose) Polymerases in Plants and Their Human Counterparts: Parallels and Peculiarities
por: Rissel, Dagmar, et al.
Publicado: (2019)

Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy
por: Singh, Bijay, et al.
Publicado: (2020)

Developmental changes of poly(ADP-ribose) polymerase expression in Sarcophaga peregrina
por: Masutani, Mitsuko, et al.
Publicado: (2004)

Research Advances in the Role of the Poly ADP Ribose Polymerase Family in Cancer
por: Sha, Huanhuan, et al.
Publicado: (2021)

Plasma and Peritoneal Poly (ADP-Ribose) Polymerase Levels in Patients with Endometriosis
por: Kacperczyk-Bartnik, Joanna, et al.
Publicado: (2022)

Fine-Tuning of Smad Protein Function by Poly(ADP-Ribose) Polymerases and Poly(ADP-Ribose) Glycohydrolase during Transforming Growth Factor β Signaling
por: Dahl, Markus, et al.
Publicado: (2014)

Inhibition of poly(ADP-ribose) polymerase-1 or poly(ADP-ribose) glycohydrolase individually, but not in combination, leads to improved chemotherapeutic efficacy in HeLa cells
por: FENG, XIAOXING, et al.
Publicado: (2012)

Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) – Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy
por: Harrision, Daniel, et al.
Publicado: (2020)

Poly (ADP-ribose) polymerase inhibitor exposure reduces ovarian reserve followed by dysfunction in granulosa cells
por: Nakamura, Kentaro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_da331bqgm6uk8l1ivmj93v645e